|
Volumn 18, Issue 1, 2007, Pages 1-23
|
Calcineurin inhibitor-free protocols: risks and benefits.
a a a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AZATHIOPRINE;
CALCINEURIN;
CYCLOSPORIN;
DRUG DERIVATIVE;
IMMUNOSUPPRESSIVE AGENT;
MYCOPHENOLIC ACID;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
RAPAMYCIN;
CHRONIC KIDNEY FAILURE;
DRUG ADMINISTRATION;
DRUG ANTAGONISM;
DRUG COMBINATION;
DRUG EFFECT;
EDITORIAL;
GRAFT REJECTION;
GRAFT SURVIVAL;
HUMAN;
KIDNEY TRANSPLANTATION;
PATIENT SELECTION;
RISK ASSESSMENT;
TREATMENT OUTCOME;
AZATHIOPRINE;
CALCINEURIN;
CYCLOSPORINE;
DRUG ADMINISTRATION SCHEDULE;
DRUG THERAPY, COMBINATION;
GRAFT REJECTION;
GRAFT SURVIVAL;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY FAILURE, CHRONIC;
KIDNEY TRANSPLANTATION;
MYCOPHENOLIC ACID;
PATIENT SELECTION;
RISK ASSESSMENT;
SIROLIMUS;
TREATMENT OUTCOME;
|
EID: 34248159572
PISSN: 13192442
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
Times cited : (20)
|
References (112)
|